Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Recruiting · Not applicable · NCT06496256
Conditions: Prostate Cancer
At a glance
- Research payments reported, 2025
- $121,919
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 84
About the trial
- Sponsor
- Palette Life Sciences, Inc. (with Teleflex)
- Tested
- Barrigel (device), Transrectal Ultrasound (device)
- Dates
- Started 2024-10-31; completion 2028-12-31
- Results posted
- Not yet
Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.
From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Teleflex LLC reported $121,919 in research payments for this study in 2025 (10 payments).
Products named: Weck, Barrigel
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Pratik M. Patel, MD Urology · Gilbert, AZ
- Martin T. King, MD PHD Radiation Oncology · Boston, MA
- Glen Gejerman, MD Radiation Oncology · Hackensack, NJ
- Brian C. Mazzarella, MD Urology · Lakeway, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Summit Medical Group PA $58,400
- Brigham and Women's Physicians $30,294
- Urology Austin PLLC $20,300
- Arizona State Urological Institute $12,925
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.